XPH · State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF ETF
SPDR SERIES TRUST
$70.93
-0.14%
At close · Sep 4
Net assets $428,431,440
Holdings67
1 month
+0.58%
Year to date
+26.91%
52-week range
$45.80–$74.35
30-session avg volume
140,659
Market performance
Adjusted close · up to five years
Fund profile
- Structure
- Open-end / ETF
- SEC series
- S000012321
- Report date
- Jun 30, 2026
- Holdings coverage
- Full reported portfolio
Portfolio concentration
Top 10 holdings28.87%
Calculated only when the SEC filing is stored with complete portfolio coverage.
Asset allocation
EC99.95%
STIV8.64%
Country allocation
US98.39%
CA3.09%
IE3.02%
GB1.57%
SG1.57%
KY0.96%
Portfolio holdings
Latest linked SEC Form NPORT-P report.
| Holding | Ticker / CUSIP | Value | Weight |
|---|---|---|---|
| State Street Global Advisors | 857492706 | $36,754,275 | 8.58% |
| Definium Therapeutics Inc | DFTX | $13,233,152 | 3.09% |
| MBX Biosciences Inc | MBX | $11,645,102 | 2.72% |
| Alumis Inc | ALMS | $9,171,220 | 2.14% |
| AtaiBeckley Inc | ATAI | $9,114,855 | 2.13% |
| Trevi Therapeutics Inc | TRVI | $9,099,204 | 2.12% |
| Enliven Therapeutics Inc | ELVN | $8,967,322 | 2.09% |
| Amylyx Pharmaceuticals Inc | AMLX | $8,723,549 | 2.04% |
| VeraDermics Inc | MANE | $8,643,911 | 2.02% |
| Ligand Pharmaceuticals Inc | LGND | $8,323,914 | 1.94% |
| Nuvation Bio Inc | NUVB | $8,107,990 | 1.89% |
| Edgewise Therapeutics Inc | EWTX | $8,068,834 | 1.88% |
| Nektar Therapeutics | NKTR | $8,038,063 | 1.88% |
| Liquidia Corp | LQDA | $7,988,547 | 1.86% |
| Maze Therapeutics Inc | MAZE | $7,932,367 | 1.85% |
| Harrow Inc | HROW | $7,734,212 | 1.81% |
| EyePoint Inc | EYPT | $7,582,318 | 1.77% |
| Amneal Pharmaceuticals Inc | AMRX | $7,387,043 | 1.72% |
| Ocular Therapeutix Inc | OCUL | $7,345,684 | 1.71% |
| Corcept Therapeutics Inc | CORT | $7,276,672 | 1.70% |
| Crinetics Pharmaceuticals Inc | CRNX | $7,128,285 | 1.66% |
| Pacira BioSciences Inc | PCRX | $7,082,086 | 1.65% |
| Merck & Co Inc | MRK | $7,054,650 | 1.65% |
| Indivior Pharmaceuticals Inc | INDV | $7,042,307 | 1.64% |
| Elanco Animal Health Inc | ELAN | $7,035,138 | 1.64% |
| Johnson & Johnson | JNJ | $6,963,095 | 1.63% |
| Eli Lilly & Co | LLY | $6,905,119 | 1.61% |
| Jazz Pharmaceuticals PLC | 000000000 | $6,861,139 | 1.60% |
| Collegium Pharmaceutical Inc | COLL | $6,800,749 | 1.59% |
| Bristol-Myers Squibb Co | BMY | $6,775,305 | 1.58% |
| Supernus Pharmaceuticals Inc | SUPN | $6,743,903 | 1.57% |
| Royalty Pharma PLC | 000000000 | $6,723,634 | 1.57% |
| Tarsus Pharmaceuticals Inc | TARS | $6,716,264 | 1.57% |
| WaVe Life Sciences Ltd | 000000000 | $6,711,079 | 1.57% |
| Harmony Biosciences Holdings Inc | HRMY | $6,709,089 | 1.57% |
| Organon & Co | OGN | $6,615,996 | 1.54% |
| ANI Pharmaceuticals Inc | ANIP | $6,612,549 | 1.54% |
| Viatris Inc | VTRS | $6,583,372 | 1.54% |
| Esperion Therapeutics Inc | 29664W105 | $6,579,445 | 1.54% |
| Axsome Therapeutics Inc | AXSM | $6,496,441 | 1.52% |
| Innoviva Inc | INVA | $6,455,431 | 1.51% |
| BioAge Labs Inc | BIOA | $6,425,370 | 1.50% |
| Prestige Consumer Healthcare Inc | PBH | $6,290,219 | 1.47% |
| Rapport Therapeutics Inc | RAPP | $6,161,076 | 1.44% |
| Pfizer Inc | PFE | $6,149,671 | 1.44% |
| Omeros Corp | OMER | $6,095,530 | 1.42% |
| Perrigo Co PLC | 000000000 | $6,081,298 | 1.42% |
| Xeris Biopharma Holdings Inc | XERS | $5,966,191 | 1.39% |
| Zoetis Inc | ZTS | $5,779,556 | 1.35% |
| Eton Pharmaceuticals Inc | ETON | $5,590,511 | 1.30% |